China's drug regulator has also accelerated approvals of domestically developed innovative products. The National Medical ...

Back in February, newly-confirmed Secretary of Health and & Human Services (HHS) Robert F. Kennedy Jr. promised to reverse decades of industry capture ...

A new U.S.-led alliance to secure semiconductor manufacturing highlights a deeper shift in global techno-geopolitics — and ...

Dec 24 (Reuters) - Sanofi (SASY.PA) said on Wednesday it will buy U.S. biotech Dynavax Technologies (DVAX.O) for around $2.2 ...

Large pharmaceutical companies are entering a period of renewed relevance as therapeutic innovation accelerates, particularly ...

The overall leadership outlook was positive in a recent survey but varied between executives in the U.S. and those overseas.

In this Waste360 Q&A, Kristin Aldred discusses existing rules around home healthcare waste disposal and gaps in regulation ...

Adding another potential wrinkle to the industry’s work with China is the Biosecure Act, a piece of China-targeting national ...

In today’s Pharma Pulse, Samsung Biologics enters the US market with a $280 million site acquisition, AstraZeneca secures a ...

A push to reshore some drug production and progress in advanced manufacturing technologies have been prominent trends this year, industry leaders say.

Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...

For more than five years, pharma companies and PBMs have managed to avoid disclosing the actual prices of prescription drugs.